Celiac disease (CD) is a major public health problem affecting at least 1% of the general population and leading to significant morbidity and mortality. Despite tremendous progress in the past decade, CD is still under-diagnosed due to low awareness and lack of a comprehensive screening program. Applications of highly sensitive and specific serological markers such as autoantibodies to tissue transglutaminase (tTG) suggest that up to 4% of the general population may have CD. The natural history of CD is only partially understood and the boundaries between clinical and subclinical disease remain blurred. While early detection and treatment with gluten-free diet (GFD) seems logical, the evidence is lacking to inform optimal timing, intensity and duration of gluten exclusion. Our unique large prospective study of children at high-risk of CD (R01 DK50979, 9/1995-4/2011, M. Rewers, P.I.) has answered some of the key research priorities identified by expert committees. In this competing renewal application we are proposing to address additional unanswered challenges facing celiac research today:
Specific Aim 1. Determine the cumulative incidence, genetic, and environmental predictors of persistent tTG and CD by age 15 years. We will accomplish this goal through continuing follow-up for development of tTG and CD of already established cohorts: A) General population children with high risk HLA-DQ genotypes (n=1,268;current median age 10.8 yr);B) Non-diabetic first degree relatives of patients with type 1 diabetes (n=1,082;current median age 13.6 yr);C) Children with type 1 diabetes (T1D) (n=4,677); During the proposed 5-year follow-up, 66% of the study participants in cohorts A and B will achieve 15 yrs of age and all will be at least 10. This will allow for a comprehensive assessment of the natural history of CD throughout childhood and adolescence. Our preliminary data suggest that more than 60% childhood CD cases in the U.S. develop after age 5. It is likely that the genetic and environmental causes of CD manifesting in older children differ from those in pre-school children. Future screening programs need to take this into account.
Specific Aim 2. Define predictors of clinically relevant outcomes: growth, micronutrient deficiencies, bone mineralization and quality of life in a large prospective followed cohort of children with screening-identified tTG+ and appropriate controls.
Specific Aim 3. Map out the evolution of humoral response to wheat gliadins and selected glutenins, hordeins and secalins from early childhood to adulthood.

Public Health Relevance

Celiac disease (CD) is a major public health problem affecting at least 1% of the general population and leading to significant morbidity and mortality. Despite tremendous progress in the past decade, CD is still under-diagnosed due to low awareness and lack of a comprehensive screening program. The natural history of CD is only partially understood and the boundaries between clinical and subclinical disease remain blurred. While early detection and treatment with gluten-free diet (GFD) seems logical, the evidence is lacking to inform optimal timing, intensity and duration of gluten exclusion. Our unique large prospective study of children at high-risk of CD has answered some of the key research priorities identified by expert committees. In this competing renewal application we are proposing to: 1) determine the incidence, genetic, and environmental predictors of CD by age 15 years;2) define predictors of clinically relevant outcomes: growth, micronutrient deficiencies, bone mineralization and quality of life of children with screening-identified CD;and 3) map out the evolution of immune response to wheat proteins from early childhood to adulthood.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK050979-16
Application #
8291233
Study Section
Kidney, Nutrition, Obesity and Diabetes (KNOD)
Program Officer
Hamilton, Frank A
Project Start
1995-09-30
Project End
2015-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
16
Fiscal Year
2012
Total Cost
$327,703
Indirect Cost
$110,203
Name
University of Colorado Denver
Department
Pediatrics
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Steck, Andrea K; Dong, Fran; Frohnert, Brigitte I et al. (2018) Predicting progression to diabetes in islet autoantibody positive children. J Autoimmun 90:59-63
Liu, Chih-Wei; Bramer, Lisa; Webb-Robertson, Bobbie-Jo et al. (2018) Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression. J Proteomics 172:100-110
Liu, Edwin; Dong, Fran; BarĂ³n, Anna E et al. (2017) High Incidence of Celiac Disease in a Long-term Study of Adolescents With Susceptibility Genotypes. Gastroenterology 152:1329-1336.e1
Frohnert, Brigitte I; Ide, Lisa; Dong, Fran et al. (2017) Late-onset islet autoimmunity in childhood: the Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 60:998-1006
Liu, Chih-Wei; Bramer, Lisa; Webb-Robertson, Bobbie-Jo et al. (2017) Temporal profiles of plasma proteome during childhood development. J Proteomics 152:321-328
Gesualdo, Patricia D; Bautista, Kimberly A; Waugh, Kathleen C et al. (2016) Feasibility of screening for T1D and celiac disease in a pediatric clinic setting. Pediatr Diabetes 17:441-8
Steck, Andrea K; Dong, Fran; Waugh, Kathleen et al. (2016) Predictors of slow progression to diabetes in children with multiple islet autoantibodies. J Autoimmun 72:113-7
Simmons, Kimber M; McFann, Kim; Taki, Iman et al. (2016) Reduced Bone Mineral Density Is Associated with Celiac Disease Autoimmunity in Children with Type 1 Diabetes. J Pediatr 169:44-8.e1
Zhao, Zhiyuan; Miao, Dongmei; Waugh, Kathleen et al. (2016) Higher Sensitivity and Earlier Identification of Celiac Disease Autoimmunity by a Nonradioactive Assay for Transglutaminase Autoantibodies. J Immunol Res 2016:2904563
Zhao, Zhiyuan; Miao, Dongmei; Michels, Aaron et al. (2016) A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease. J Immunol Methods 430:28-32

Showing the most recent 10 out of 50 publications